Cellular Therapy Option for Treatment of Central Nervous System EBV-PTLD
Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br />
Susan Prockop, MD, associate attending in pediatrics at Memorial Sloan Kettering Cancer Center, discusses an option available for the treatment of central nervous system (CNS) Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).
According to a subset analysis, patients are at very high risk of developing this disease after hematopoietic stem cell transplant or solid organ transplant and the modalities available are still limited, Prockop says. A high dose of radiation can be debilitating with significant side effects, so adoptive immunotherapy with EBV-specific T cells is a good option for these patients.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
